Digital Therapeutics is Estimated to Witness High Growth Owing to Rising Prevalence of Chronic Diseases

Comments · 107 Views

Digital Therapeutics (DTx) are evidence-based therapeutic interventions driven by software to prevent, manage, or treat a medical disorder or disease. DTx are a part of digital health that deliver therapeutic interventions directly to patients via evidence-based, clinically-evaluated softw

Digital therapeutics involve the use of digital and online health technologies to treat various medical and psychological conditions. This includes apps, software, wearables and connected devices, which provide therapy through evidence-based techniques such as cognitive behavioral therapy (CBT), virtual reality, and other digital interfaces. These are utilized by patients to treat and manage a wide range of chronic conditions like diabetes, cancer, mental health disorders, musculoskeletal disorders, and more, with or without clinician support.

The global digital therapeutics market is estimated to be valued at US$ 6.6 Bn in 2023 and is expected to exhibit a CAGR of 20.5% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
The rising prevalence of chronic diseases across the globe has augmented the demand for cost-effective treatment options. According to the World Health Organization (WHO), chronic diseases accounted for approximately 60% of total reported deaths in the world in 2020. Digital therapeutics aids in the management of chronic conditions by enabling remote monitoring of vital health parameters, lifestyle management, adherence to treatment protocols and access to therapy from anywhere. In addition, they leverage mobile health technologies and have the potential to reduce healthcare costs by preventing more severe exacerbation of diseases. Another key driver for digital therapeutics is the growing adoption of smartphones and wireless networking globally which has increased the accessibility of digital interventions. These factors are expected to propel the digital therapeutics market growth over the forecast period.

SWOT Analysis
Strength: Digital therapeutics can provide cost-effective and accessible treatment options for patients. As these solutions do not require visits to a healthcare facility, they improves the reach of treatment. Remote monitoring allows continual patient supervision and intervention. Digital therapeutics have personalized treatment protocols which can be tailored according to an individual's need and medical conditions.

Weakness: Lack of awareness among patients and healthcare providers regarding benefits of digital therapeutics. Integration of digital therapeutics within conventional healthcare practice can be challenging. Data privacy and security concerns may limit the wide-scale adoption of such technologies.

Opportunity: Growing prevalence of chronic diseases worldwide is generating increased demand for cost-effective treatment options. This provides scope for digital therapeutics to complement or substitute certain conventional therapies. Telehealth and remote care models are gaining prominence during the pandemic which favors digital solutions. Partnerships between digital therapy developers and pharma companies can help expand access and commercialization.

Threats: Delayed regulatory approvals and reimbursement coverage that impact market access for digital therapeutics. Limited evidence regarding real-world effectiveness and long term impact on health outcomes compared to traditional treatments. Entry of new players may lead to increasing competitive pressure on pricing.

Key Takeaways
The global digital therapeutics market is expected to witness high growth. Propelled by a substantial increase in healthcare costs and chronic disease burden globally, digital therapeutics are emerging as a cost-effective treatment alternative. The market size for digital therapeutics was US$ 6.6 Bn in 2023 and is estimated to reach nearly US$ 13 Bn by 2030, expanding at a CAGR of 20.5% during the forecast period.

The North America dominated the digital therapeutics market in 2023, accounting for over 40% of the global demand. This is attributed to factors such as higher penetration of apps and wearables, focus on preventive healthcare to cut costs, and supportive regulatory framework. Asia Pacific is anticipated to showcase the fastest growth during the forecast period driven by the increasing focus of domestic governments to develop digital healthcare infrastructure in countries such as India, China, and Japan. Rapid expansion of telehealth and online consultation services in the region is furthering the growth of digital therapeutics market in Asia Pacific.
Key players operating in the digital therapeutics market are Happify, Inc., 2Morrow, Inc., Akili Interactive Labs, Inc., Click Therapeutics, Inc., and Fitbit, Inc.. These players have developed a variety of evidence-based digital therapeutic solutions targeting a wide range of disease conditions including diabetes, hypertension, COPD, insomnia, and others. Strategic collaborations with pharma companies and healthcare providers are helping them strengthen commercial presence across global markets.

Comments
Free Download Share Your Social Apps